FDA Updates Lumateperone Label With Relapse-Prevention Data - Top_Thought_Leaders - MDSpire

FDA Updates Lumateperone Label With Relapse-Prevention Data

Label update incorporates randomized withdrawal trial findings showing delayed time to relapse and consistent safety profile in schizophrenia

  • By

  • Kathryn Wighton

  • April 29, 2026

  • 2 min

Share

Top Thought Leaders in Pathology

Brief introduction explaining scope and methodology.

Original Source(s)

FDA Updates Lumateperone Label With Relapse-Prevention Data

  • by Kathryn Wighton

  • April 29, 2026

Related Content

Physicians Exiting Practice Earlier

Researchers identify burnout-associated workplace pressures and caregiving responsibilities as major contributors to physician attrition.

Dual-Site aiTBS for Suicidal Ideation in Adolescents With Major Depressive Disorder: A Randomized Clinical

Assessing directional connections between symptoms, cognition, insight, and real-life functioning in schizophrenia: a partial ancestor graphs analysis